Levosert Easy

Levonorgestrel, the active ingredient in Levosert Easy, is a progestogen presented as an intrauterine system for intrauterine use. It provides long‑acting reversible contraception and can also be used to manage heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Levosert Easy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under strict quality controls, and our distribution network ensures timely delivery and regulatory compliance for each shipment.

Levonorgestrel delivered via an intrauterine system acts on the reproductive hormonal pathway to provide contraception and related therapeutic benefits.

Contraception: Provides highly effective, long‑acting reversible contraception for women of reproductive age. Heavy menstrual bleeding: Reduces menstrual blood loss and improves bleeding patterns in women with menorrhagia. Endometrial protection: Induces endometrial atrophy, decreasing the risk of hyperplasia during estrogen therapy.

Levosert Easy may be associated with a range of local and systemic adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or abdominal pain - Headache - Breast tenderness - Acne or skin changes

Serious or Rare Side Effects: - Uterine perforation during insertion - Device expulsion or displacement - Pelvic inflammatory infection - Ectopic pregnancy if contraception fails - Severe allergic reaction (anaphylaxis) - Ovarian cyst formation

Before insertion of Levosert Easy, clinicians should observe several precautionary measures to ensure safety and optimal efficacy.

Pregnancy testing: Confirm the patient is not pregnant prior to device placement. Uterine abnormalities screening: Perform ultrasound to rule out fibroids, septa, or other structural issues. Infection risk: Insert under aseptic conditions and treat any active pelvic infection before placement. Hormone‑sensitive conditions: Avoid use in women with known or suspected breast cancer or other hormone‑dependent tumors. Breastfeeding: Discuss benefits and risks with lactating patients; use with caution. Store at ambient temperature: Keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from an intrauterine system can interact with other medicines that affect hormone metabolism or immune response.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampicin, carbamazepine): may reduce levonorgestrel efficacy. - Antifungal azoles (e.g., ketoconazole): may increase systemic exposure. - Protease inhibitors (e.g., ritonavir): may alter hormone levels.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics (e.g., tetracycline): may modestly affect contraceptive effectiveness. - Certain anticonvulsants (e.g., phenytoin): may lower hormone concentrations. - Herbal supplements (e.g., St. John’s wort): may decrease contraceptive reliability.